Tannock IF - Search Results

1

Chemotherapy-based treatment for castration-resistant prostate cancer.

Seruga B, Tannock IF. Seruga B, et al. Among authors: tannock if. J Clin Oncol. 2011 Sep 20;29(27):3686-94. doi: 10.1200/JCO.2010.34.3996. Epub 2011 Aug 15. J Clin Oncol. 2011. PMID: 21844499 Review.

2

Bone metastases: pathophysiology and management policy.

Nielsen OS, Munro AJ, Tannock IF. Nielsen OS, et al. Among authors: tannock if. J Clin Oncol. 1991 Mar;9(3):509-24. doi: 10.1200/JCO.1991.9.3.509. J Clin Oncol. 1991. PMID: 1705581 Review.

3

A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer.

Tannock IF, Boyd NF, DeBoer G, Erlichman C, Fine S, Larocque G, Mayers C, Perrault D, Sutherland H. Tannock IF, et al. J Clin Oncol. 1988 Sep;6(9):1377-87. doi: 10.1200/JCO.1988.6.9.1377. J Clin Oncol. 1988. PMID: 2458438 Clinical Trial.

4

Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer.

Tannock IF, Browman G. Tannock IF, et al. J Clin Oncol. 1986 Jul;4(7):1121-6. doi: 10.1200/JCO.1986.4.7.1121. J Clin Oncol. 1986. PMID: 3522819 Review.

5

Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate?

Tannock IF. Tannock IF. J Clin Oncol. 1985 Jul;3(7):1013-21. doi: 10.1200/JCO.1985.3.7.1013. J Clin Oncol. 1985. PMID: 3894584 Clinical Trial.

6

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J. Moore MJ, et al. Among authors: tannock if. J Clin Oncol. 1994 Apr;12(4):689-94. doi: 10.1200/JCO.1994.12.4.689. J Clin Oncol. 1994. PMID: 7512127 Clinical Trial.

7

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Tannock IF, et al. J Clin Oncol. 1996 Jun;14(6):1756-64. doi: 10.1200/JCO.1996.14.6.1756. J Clin Oncol. 1996. PMID: 8656243 Clinical Trial.

8

Treatment of cancer with radiation and drugs.

Tannock IF. Tannock IF. J Clin Oncol. 1996 Dec;14(12):3156-74. doi: 10.1200/JCO.1996.14.12.3156. J Clin Oncol. 1996. PMID: 8955662 Review.

9

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

Bloomfield DJ, Krahn MD, Neogi T, Panzarella T, Smith TJ, Warde P, Willan AR, Ernst S, Moore MJ, Neville A, Tannock IF. Bloomfield DJ, et al. Among authors: tannock if. J Clin Oncol. 1998 Jun;16(6):2272-9. doi: 10.1200/JCO.1998.16.6.2272. J Clin Oncol. 1998. PMID: 9626231 Clinical Trial.

10

Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.

Phillips KA, Tannock IF. Phillips KA, et al. Among authors: tannock if. J Clin Oncol. 1998 Sep;16(9):3179-90. doi: 10.1200/JCO.1998.16.9.3179. J Clin Oncol. 1998. PMID: 9738590 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

494 results

Search Page